1. Show article details.

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    Benzinga – 8:11 AM ET 08/19/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  2. Show article details.

    Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday

    Benzinga – 3:59 AM ET 07/20/2022

    Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday

  3. Show article details.

    This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session

    Benzinga – 12:04 PM ET 07/19/2022

    This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session

  4. Show article details.

    Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday

    Benzinga – 4:35 AM ET 07/05/2022

  5. Show article details.

    Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session

    Benzinga – 12:06 PM ET 07/01/2022

    Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session

  6. Show article details.

    12 Health Care Stocks Moving In Thursday's After-Market Session

    Benzinga – 5:41 PM ET 06/30/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

  7. Show article details.

    This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday

    Benzinga – 4:55 AM ET 06/30/2022

  8. Show article details.

    Why Is Allena Pharmaceuticals Jumping By 207%? 45 Stocks Moving In Wednesday's Mid-Day Session

    Benzinga – 12:32 PM ET 06/29/2022

  9. Show article details.

    LiveOne And 24 Stocks Moving Premarket

    Benzinga – 6:32 AM ET 06/29/2022

    Don't forget to check out our premarket coverage here .

  10. Show article details.

    This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday

    Benzinga – 4:23 AM ET 06/28/2022

    This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday

  11. Show article details.

    Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session

    Benzinga – 12:26 PM ET 06/27/2022

     Gainers Evofem Biosciences, Inc. rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade.    Losers Borqs Technologies, Inc. shares fell 23% to $2.19 following effect of 1:16 reverse stock split.  

  12. Show article details.

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    Benzinga – 8:40 AM ET 06/27/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  13. Show article details.

    Epizyme + 20 Stocks Moving In Monday's Pre-Market Session

    Benzinga – 6:31 AM ET 06/27/2022

    Don't forget to check out our premarket coverage here .

  14. Show article details.

    Carnival Surges Over 12%, Here's 75 Biggest Movers From Friday

    Benzinga – 4:26 AM ET 06/27/2022

       

  15. Show article details.

    91 Biggest Movers From Friday

    Benzinga – 4:28 AM ET 06/13/2022

    91 Biggest Movers From Friday

  16. Show article details.

    44 Stocks Moving In Friday's Mid-Day Session

    Benzinga – 12:07 PM ET 06/10/2022

    44 Stocks Moving In Friday's Mid-Day Session

  17. Show article details.

    BRIEF-Tenax Therapeutics Files Prospectus Related To Resale Of Up To 21.2 Million Shares Of Common Stock By Certain Selling Stockholders - SEC Filing

    Reuters – 6:12 PM ET 05/25/2022

    Tenax Therapeutics Inc (TENX): * TENAX THERAPEUTICS FILES PROSPECTUS RELATED TO RESALE OF UP TO 21.2 MILLION SHARES OF COMMON STOCK BY CERTAIN SELLING STOCKHOLDERS - SEC FILING Further company coverage:

  18. Show article details.

    Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)

    Business Wire – 8:30 AM ET 05/25/2022

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will host a key opinion leader webinar about TNX-201, in development as a potential treatment for pulmonary arterial hypertension, on Thursday, June 2, 2022 at 11:00a...

  19. Show article details.

    TENX: 1Q:22 Financial and Operational Review

    Benzinga – 8:41 AM ET 05/24/2022

    By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Tenax Therapeutics, Inc. reported first quarter 2022 results on May 16, 2022 via its filing of Form 10-Q with the SEC. Highlights for 2022 include: ➢ TNX-102 patent allowed by USPTO - January 2022. ➢ Transition to oral levosimendan open label extension completed - January 2022.

  20. Show article details.

    BRIEF-Tenax Announces Successful Comparative Pharmacokinetic Study Of Pulmonary Arterial Hypertension Treatment

    Reuters – 9:11 AM ET 05/23/2022

    Tenax Therapeutics Inc (TENX): * TENAX THERAPEUTICS ANNOUNCES SUCCESSFUL COMPARATIVE PHARMACOKINETIC STUDY OF TNX-201 FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION. * Tenax Therapeutics Inc (TENX) - MANUFACTURING UNDERWAY TO SUPPORT PHASE 3 PAH STUDY.

Page:

Today's and Upcoming Events

  • Nov
    14

    TENX to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    11

    TENX announced Q2 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.